|Year : 2021 | Volume
| Issue : 1 | Page : 112-115
Anti-CD6 humanized monoclonal antibody itolizumab, halts disease progression and severity of acute respiratory distress syndrome in COVID-19 disease: A case study
Hemant P Thacker1, Amit Dhekane2, Nivedita Wadhwa2, Shalaka Patil2
1 Department of General Medicine, Bhatia Hospital, Mumbai, Maharashtra, India
2 Department of Critical Care Medicine, Bhatia Hospital, Mumbai, Maharashtra, India
|Date of Submission||30-Jul-2020|
|Date of Decision||13-Aug-2020|
|Date of Acceptance||07-Sep-2020|
|Date of Web Publication||31-Jan-2021|
Dr. Hemant P Thacker
Bhatia Hospital, Tardeo Road, Old Chikalwadi, Grant Road (W), Tardeo, Mumbai - 400 007, Maharashtra
Source of Support: None, Conflict of Interest: None
In COVID-19 patients, cytokine release syndrome plays a critical role in disease progression. Itolizumab inhibits T-cell proliferation and differentiation, thereby modulating imminent cytokine storm. Here, we report a case of a 44-year-old male patient with confirmed COVID-19 and oxygen saturation (SpO2) of 88% on room air. A chest X-ray revealed dense opacification. High levels of inflammatory markers such as C-reactive protein (CRP) and ferritin were observed. The patient's SpO2 decreased to 87% on day 4 despite the best supportive care. Itolizumab was then administered at 1.6 mg/kg along with high flow oxygen. The patient's SpO2 values improved to 95% and 97% on 4th- and 5th-day postinfusion, respectively. CRP and ferritin levels decreased by 85.96% and 24.48%, respectively, along with radiological improvement. The patient was discharged on the 7th day postinfusion in a clinically stable condition. This is the first report of an anti-CD6 humanized monoclonal antibody, itolizumab, given to a patient with moderate-to-severe COVID-19 disease that showed a reduction in hyperinflammation, leading to clinical and radiological improvement.
Keywords: Acute respiratory distress syndrome, CD6, COVID-19, cytokine storm, hyperinflammation, itolizumab
|How to cite this article:|
Thacker HP, Dhekane A, Wadhwa N, Patil S. Anti-CD6 humanized monoclonal antibody itolizumab, halts disease progression and severity of acute respiratory distress syndrome in COVID-19 disease: A case study. Indian J Respir Care 2021;10:112-5
|How to cite this URL:|
Thacker HP, Dhekane A, Wadhwa N, Patil S. Anti-CD6 humanized monoclonal antibody itolizumab, halts disease progression and severity of acute respiratory distress syndrome in COVID-19 disease: A case study. Indian J Respir Care [serial online] 2021 [cited 2021 Mar 5];10:112-5. Available from: http://www.ijrc.in/text.asp?2021/10/1/112/308470
| Introduction|| |
Novel coronavirus disease (COVID-19) was declared a global pandemic by the World Health Organization (WHO) on March 11, 2020. With no known cure to the disease, multiple options are being considered to reduce symptoms and mortality.
COVID-19 is marked with an increase in pro-inflammatory cytokines released by activated T-cells. Uncontrolled inflammation can lead to acute respiratory distress syndrome (ARDS), sepsis, multiorgan dysfunction syndrome, and death. T-cells are activated by the binding of the activated leukocyte cell adhesion molecule (ALCAM/CD166) found on antigen-presenting cells, with the CD6 receptor on T-cells [Figure 1]a. This is a crucial step in T-cell proliferation to form helper T-cells (Th1 and Th17 cells), which in turn produce inflammatory cytokines such as interferon gamma, tumor necrosis factor-alpha, interleukin (IL)-2, IL-6, IL-10, IL-17, IL-22, granulocyte colony-stimulating factor, and others [Figure 1]b.
|Figure 1: (a) Binding of itolizumab to domain 1 of naïve T-cell, (b) T-cell proliferation and cytokine storm in the absence of itolizumab, (c) absence of T-cell proliferation and cytokine storm in the presence of itolizumab|
Click here to view
Itolizumab is a humanized recombinant immunoglobulin G1 monoclonal antibody which targets domain 1 of CD6, thereby modulating T-lymphocyte activation, proliferation, and differentiation induced by CD6 co-stimulation [Figure 1]c. It does not cause T-cell depletion as it does not inhibit soluble ALCAM binding. In addition, it is believed that the presence of CD6 in T- and B-cells provides a wider range of immunomodulating effects.
Here, we present a case study of a 44-year-old, COVID-19 male patient with multiple comorbidities treated with itolizumab, who was deteriorating with low oxygen saturation (SpO2) of 87% and high inflammatory markers despite best supportive care. The patient's medical history included diabetes, hypertension, and stroke in 2014.
| Case Report|| |
The patient was presented on June 2, 2020, with a history of fever, cough, weakness, and body pain. His body weight was 62 kg. There was no history of diarrhea, headache, or sore throat. The patient was on antihypertensive (amlodipine 5 mg OD) and antidiabetic drugs including SGLT2 inhibitor (remogliflozin 500 mg BD), DPP-IV inhibitor (evogliptin 5 mg OD), rosuvastatin 20 mg OD and aspirin 150 mg OD. The patient tested positive for SARS-CoV-2 infection by reverse transcription- polymerase chain reaction (RT-PCR).
On examination, his respiratory rate (RR) was 22/min, with SpO2 of 88% on room air. Upon admission, the patient was administered oxygen (2–4 L/min) through nasal prongs and the SpO2 improved to 92%. His clinical status score was 4 based on an 8-point ordinal scale.
On 3rd June, the patient was shifted to a Venturi mask with an oxygen flow of 8 L/min, and his oxygen saturation was maintained at 92%. His inflammatory markers were elevated: C-reactive protein (CRP) 183.24 mg/mL, ferritin 633.7 ng/mL, and his chest X-ray revealed bilateral basal peripheral and upper lobe complete dense opacification.
On 4th June, the oxygen flow was increased to 12 L/min through high flow nasal cannula (HFNC), and the patient maintained SpO2 of 90%. Chest X-ray revealed persistent opacities in bilateral basal peripheral zones.
On 5th June, the patient had a reduced SpO2 of 87% with HFNC (12–14 L/min) and RR of 32/min. Itolizumab (1.6 mg/kg) was consequently administered as an intravenous infusion with 250 ml of normal saline for 5–6 h after premedication with hydrocortisone 100 mg IV, 30 min before itolizumab infusion. The infusion was well tolerated. The patient continued to be on high flow oxygen (10–12 L/min) until 4-day postitolizumab infusion and maintained a SpO2 of 95%.
Five-day postinfusion, the patient was shifted to a Venturi mask and then to oxygen by nasal prongs; oxygen flow was reduced to 4–6 L/min. The patient maintained a SpO2 of 97%, and his chest X-ray revealed signs of improvement with fibrotic changes.
Six-day postinfusion, the patient was clinically stable and was off oxygen. The clinical improvement as per the WHO ordinal scale [Table 1] is shown in [Figure 2]. A significant reduction in inflammatory markers such as serum CRP and ferritin (25.73 mg/mL and 478.6 ng/mL, respectively) was also observed. In addition, the radiological improvement was evident as shown by healing with fibrosis.
|Table 1: World Health Organizations ordinal scale for clinical improvement|
Click here to view
|Figure 2: Change in patient's ordinal score from hospitalization to discharge|
Click here to view
The patient was discharged on June 11, 2020 (7-day postinfusion).
Predose chest X-ray images are provided in [Figure 3] and [Figure 4]. [Figure 5] shows a postdose image.
|Figure 5: Postdose chest X-ray image (on June 9, 2020, 5-days postitolizumab infusion)|
Click here to view
| Discussion|| |
COVID-19 is a global pandemic, and India has seen a sudden upsurge in the number of positive cases. While the majority of cases present with mild symptoms and good prognosis, around 20% of cases progress to severe and critical diseases. Several studies have shown an increase in inflammatory cytokines in COVID-19 patients.
Inflammatory markers such as procalcitonin, serum ferritin, erythrocyte sedimentation rate, CRP, and IL-6 have been shown to be correlated with prognosis in COVID-19. Serum ferritin levels increase in inflammation, liver disease, and malignancy and can highlight an overexuberant inflammatory response associated with the severity of COVID-19.
An ordinal scale for clinical improvement, published by the WHO, was used to score the patient status.
Itolizumab has been approved and marketed in India for moderate-to-severe plaque psoriasis. It has been found to reduce inflammation by blocking the CD6 receptor and thereby inhibiting various cytokines. Similar inflammatory responses have been reported in moderate-to-severe COVID-19 patients, leading to poor prognosis.
Based on this, as this patient showed high levels of pro-inflammatory markers and deterioration in spite of the best supportive care, a decision was taken to administer itolizumab.
A single dose of itolizumab at 1.6 mg/kg led to a significant decrease in CRP and ferritin levels (85.96% and 24.48%, respectively) with clinical and radiological improvement. The patient's ordinal score also showed a decline over time. The oxygen requirements of this patient changed from 12–14 L/min to 4–6 L/min on the 5th day, and he was off oxygen on the 6th-day postinfusion of itolizumab.
In this case report, itolizumab is found to be not only effective in reducing inflammatory markers and the need for oxygen but also led to concomitant radiological improvement and recovery in this COVID-19 patient in a real-world setting. The use of itolizumab offers a potential treatment option by targeting CD6.
On July 10, 2020, itolizumab has been granted restricted emergency authorization in India for the treatment of cytokine release syndrome (CRS) in moderate-to-severe ARDS due to COVID-19 by the Drug Controller General of India.
| Conclusion|| |
With itolizumab treatment, the patient showed a decline in CRP, ferritin, and oxygen requirement, along with radiological and clinical improvement. Itolizumab is found to be effective in reducing hyperinflammation, leading to a recovery in this COVID-19 patient with moderate-to-severe disease. While no approved or evidence-based treatment options are available, itolizumab promises potential in the treatment of CRS in moderate-to-severe ARDS due to COVID-19. Larger studies can further validate these findings.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understands that his name and initials will not be published, and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LF. The trinity of COVID-19: Immunity, inflammation and intervention. Nat Rev Immunol 2020;20:363-74.
Rodriguez PC, Torres-Moya R, Reyes G, Molinero C, Prada D, Lopez AM, et al
. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis. Results Immunol 2012;2:204-11.
Menon R, David BG. Itolizumab-A humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis. Clin Cosmet Investig Dermatol 2015;8:215-22.
Jayaraman K. Biocon's first-in-class anti-CD6 mAb reaches the market. Nat Biotechnol 2013;31:1062-3.
Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al
. Estimates of the severity of coronavirus disease 2019: A model-based analysis. Lancet Infect Dis 2020;20:669-77.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al.
COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-4.
Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al
. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis 2020;96:467-74.
Facciorusso A, del Prete V, Antonino M, Neve V, Crucinio N, di Leo A, et al
. Serum ferritin as a new prognostic factor in hepatocellular carcinoma patients treated with radiofrequency ablation. J Gastroenterol Hepatol 2014;29:1905-10.
Krupashankar DS, Dogra S, Kura M, Saraswat A, Budamakuntla L, Sumathy TK, et al
. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol 2014;71:484-92.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]